NAD+ vs Peptides: An Honest Side-by-Side Once you understand that one is a systemic coenzyme and the other is a targeted signal, the comparison stops being about which wins and becomes about which fits
With an estimated one in eight adults now taking a GLP-1, experts fear that vulnerable patients might start misusing the drugs to achieve weight loss at any cost
While the scale might show progress, what's happening beneath the surface could tell a more complex story -- one where hard-earned muscle disappears alongside skeletal strength, setting the stage for metabolic slowdown, increased fracture risk, and accelerated aging
Tool: Using Salt to Support Fasting (39:42) Tool: Ideal Feeding Window Guidelines
The Baller - $349 The ultimate reset
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPAKIDNEY trial